Newsroom
Discover the latest news and updates from Almirall.
Quick Links
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
Discover the latest news and updates from Almirall.
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
579 results
Published on 29 October 2026
Today, on World Psoriasis Day, we’re looking beyond the visible and raising awareness of the impact psoriasis can have beyond the skin.
In a digital world increasingly shaped by filters and edited images, the realities of living with a visible skin condition can easily go unseen. Psoriasis is visible on the skin, but its psychological burden may be much less apparent and can be an important part of the experience of people living with the disease.
In collaboration with IFPA, we’re helping bring greater visibility to this often less visible side of psoriasis, encouraging a deeper understanding of the experiences behind the symptoms and the impact the condition can have on people’s lives.
World Psoriasis Day is also an opportunity to listen, learn and continue building awareness around the realities faced by people living with psoriasis.
Because understanding psoriasis means looking beyond what we can see.
Published on 14 October 2026
Skin conditions go far beyond the surface. They can have a profound impact on people's daily lives, affecting physical health, emotional wellbeing and social connections.
At Almirall, we are dedicated to medical dermatology. Through our in-house R&D capabilities and collaborations with leading strategic partners, we work to advance the scientific understanding of skin diseases and develop innovative solutions that address real patient needs.
Our pipeline focuses on areas with significant unmet medical needs, including immune-mediated diseases, non-melanoma skin cancer and rare dermatological conditions. At the same time, we are exploring next-generation technologies such as biologics, small molecules, bispecific antibodies, mRNA/LNP platforms and AI-enabled approaches to drive innovation in dermatology.
As a family-owned company, we take a long-term view, investing in scientific progress that can create lasting value for patients, healthcare professionals and the broader dermatology community.
Discover how we are helping shape the future of medical dermatology: https://www.almirall.com/innovation
Published on 5 October 2026
Last week in Vienna, we had the opportunity to connect with healthcare professionals, researchers and partners from across the global dermatology community.
As a Gold Sponsor of EADV 2026, we were proud to contribute to the exchange of scientific knowledge and discussions that help advance the understanding and management of skin diseases. Throughout the congress, we explored the latest developments in medical dermatology, shared new scientific evidence, and engaged in valuable conversations around the unmet needs and real-world impact of chronic skin conditions, including atopic dermatitis, psoriasis and actinic keratosis.
Beyond the science, EADV once again highlighted the importance of collaboration across the dermatology community. The congress brought together diverse perspectives, expertise and experiences, all united by a shared goal: improving outcomes for people living with skin diseases.
A sincere thank you to everyone who joined the discussions, attended the sessions and contributed their insights throughout the week.
Together, we continue to learn, collaborate and help shape the future of dermatology!
Watch the video for some of the key highlights from an unforgettable week at EADV 2026: https://youtu.be/uiPNPWZAbuo?si=L9-oowjbqQYPU2QV
Published on 1 October 2026
Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)[i].
At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients.
The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment.
Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.
Vienna, October, 1st, 2026 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced long-term results from ADlong, a Phase 3b open-label extension study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The late-breaking results of this long-term clinical study are presented at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna, Austria, from 30 September to 3 October 2026.
“At Almirall, we are committed to bringing scientific breakthroughs closer to patients and dermatologists,” said Dr Volker Koscielny, Chief Medical Officer at Almirall. “The results of the ADlong study extend our understanding of lebrikizumab’s long-term efficacy and safety and the sustained impact it can have on patients. These data build on the four-year interim findings published earlier this year, and are an important part of addressing real patient needs and supporting informed treatment decisions for people with moderate-to-severe atopic dermatitis.”
Sustained skin and itch improvement through week 108
Improvements in skin signs and itch observed at ADlong entry were sustained through week-108 assessment in patients continuing lebrikizumab treatment. ADlong is a 108-week extension study of earlier clinical trials with the product, providing participating patients with up to 5 years of continuous treatment exposure across the clinical development program.
Key efficacy findings at week 108 included1:
EASI-75 response: 92.9%: at least a 75% improvement in the Eczema Area and Severity Index (EASI)
EASI-90 response: 73.8%: at least a 90% improvement in EASI
IGA 0/1 response: 66.7% Investigator’s Global Assessment (IGA) score of zero or one, indicating clear or almost-clear skin
Absolute Pruritus NRS ≤4 response: 78.0% reported a Pruritus Numerical Rating Scale (NRS) score of four or less
“Atopic dermatitis is a chronic, relapsing disease, therefore treatment decisions need to consider the initial response, but importantly also whether improvements in skin signs and itch are sustained over time,” said Professor Stephan Weidinger, Department of Dermatology and Allergy, University Medical Centre Schleswig-Holstein, “The findings from the ADlong study further extend the clinical evidence of lebrikizumab for up to five years of treatment and provide valuable data to inform discussions about long-term treatment in clinical practice.”
Long-term safety consistent with previous studies
The product’s safety profile during the 108 weeks of ADlong was consistent with previous studies, and no new safety signals were identified. Five participants (2.9%) discontinued due to treatment-emergent adverse events (SAEs) and ten (5.7%) presented serious treatment-emergent adverse events; no deaths were reported. Most patients did not require topical or systemic rescue treatment.
Professor Stephan Weidinger will present the ADlong findings, Abstract LB-313, on Thursday, 1 October 2026, from 16:45 to 17:00 in Hall A, during session D2T01.4 – Late Breaking News.
The abstracts will be available at Publications | JEADV, News, & Clinical Guidelines | eadv.org
Advancing science that matters at EADV 2026
Almirall’s scientific contribution to EADV 2026 includes more than 20 abstracts presentingclinical and real-world evidence across its broad dermatology portfolio, including atopic dermatitis, psoriasis and actinic keratosis. The company is hosting two expert-led symposia on atopic dermatitis and psoriasis, alongside an interactive hub session focused on AD, supporting scientific exchange on sustained disease control, face and neck involvement in atopic dermatitis, and the wider impact of skin conditions on patients. Visitors to Almirall’s congress booth (X304, X306) will also be able to explore its R&D pipeline in medical dermatology through interactive displays and a virtual-reality experience. Almirall’s R&D spans immune-mediated skin diseases, rare dermatological diseases and non-melanoma skin cancers, with modalities including biologics and small molecules, alongside emerging approaches such as mRNA/LNP and bispecific antibodies.
About ADLong
ADlong (NCT05916365) is a 108-week, Phase 3b open-label extension study evaluating the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis. It enrolled 174 patients in Germany and Poland who had completed the 100-week ADjoin extension study following participation in ADvocate 1, ADvocate 2, ADhere or ADore. Adults and adolescents aged 12–17 years with a body weight of at least 40 kg who had previously participated in these parent clinical trials could enter ADjoin regardless of their week-16 response and continued treatment for up to further 108 weeks in the ADlong Long-term extension study.
The study was funded by Almirall, S.A.
About Lebrikizumab
Lebrikizumab (LEB) is a monoclonal antibody that selectively targets the cytokine IL-13 with high affinity, blocking its downstream signalling while avoiding broader immunosuppression and preserving IL-13 physiological clearance[ii],[iii],[iv],[v],[vi]. Lebrikizumab is approved in Europe, under the brand name Ebglyss®, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.[vii]
Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe, while Eli Lilly and Company retains rights for development and commercialization in the U.S. and the rest of the world outside Europe.
About Almirall
Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We advance the scientific understanding of skin diseases to develop innovative and differentiated treatments and solutions that address patients’ needs. Our clinical development portfolio includes four ongoing proof-of-concept (PoC)/Phase II studies and two further PoC studies planned across key areas of medical dermatology.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit almirall.com
Corporate Communications: Investor Relations
Corporate.communication@almirall.com investors@almirall.com
Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87
Media landing page: EADV 2026 Media Page | Almirall
Media password: EADV 2026 Media Page
Legal warning
This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.
1[ADlong Study] Late-Breaking Abstract: Lebrikizumab 5-Year Long-Term Extension Results in Moderate-to-Severe Atopic Dermatitis (ADlong). EADV Congress 2026 (Late-breaker).
[ii] Moyle M, Cevikbas F, Harden JL, Guttman‑Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756‑768.
[iii] Okragly AJ, Ryuzoji A, Wulur I, Daniels M, Van Horn RD, Patel CN, et al. Binding, neutralization and internalization of the interleukin‑13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535‑1547.
[iv] Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti‑IL‑13 antibody lebrikizumab. J Mol Biol. 2013;425(8):1330‑1339.
[v] Tsuji G, Yamamura K, Kawamura K, Kido‑Nakahara M, Ito T, Nakahara T. Novel therapeutic targets for the treatment of atopic dermatitis. Biomedicines. 2023;11:1303
[vi] Furue M, Ulzii D, Nakahara T, Tsuji G, Furue K, Hashimoto‑Hachiya A, et al. Implications of IL‑13Rα2 in atopic skin inflammation. Allergol Int. 2020;69:412‑416.
[vii] European Medicines Agency (EMA). Ebglyss: EPAR—Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss
Press release
PDF 180.7KB
Published on 30 September 2026
Almirall’s scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two expert-led symposia and an interactive industry AD hub session.
New clinical data show consistent efficacy and effectiveness in atopic dermatitis treatment across body regions with lebrikizumab, including high-impact areas such as the face and neck[i],[ii], while late-breaking ADlong results highlight sustained improvements in skin signs and itch with up to five years of treatment[iii].
Final two-year data from the POSITIVE clinical study demonstrate the benefits on patient overall well-being and quality of life during tildrakizumab treatment[iv],[v], and further data show evidence in patients with high disease burden and previous biologic treatment[vi],[vii].
Almirall’s commitment to medical dermatology is reflected by its Gold Sponsorship of EADV 2026 and the launch of the ‘Face It’-campaign to raise awareness of the burden of atopic dermatitis with face and neck involvement, addressing the broader impact of skin diseases on patients.
Vienna, September 30th, 2026 – Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, today announced its scientific programme at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna from 30 September to 3 October 2026. As Gold Sponsor of this year’s congress, Almirall will present more than 20 abstracts on clinical and real-world evidence spanning atopic dermatitis (AD), psoriasis (PsO) and actinic keratosis (AK), and a late-breaking abstract on the ADlong 5-year long-term extension trial of AD, presenting clinical and real-world evidence across its broad commercial portfolio to support patients and dermatologists.
Almirall is sharing new data for its biologic treatments, lebrikizumab in AD and tildrakizumab in PsO, with a focus on strengthening the evidence base in areas of high unmet patient need. These new data demonstrate positive treatment outcomes across different patient populations and body regions, including high-impact areas, alongside sustained, holistic disease control– in line with Almirall’s commitment to impactful innovation that makes a real difference to patients. Evidence for topical treatments further underscores the value of a broad product portfolio for patients and dermatologists, with data showing adherence and effectiveness of CAL/BDP PAD cream in psoriasis[viii],[ix], as well as one-year safety and efficacy data of tirbanibulin when applied to up to 100 cm2 in patients with AK on face or scalp[x].
Two expert-led, educational symposia on AD and PsO, an interactive industry hub session focused on AD and a dedicated R&D corner at the exhibition booth which features Almirall’s medical dermatology pipeline, provide opportunities for scientific exchange on the new evidence and its relevance to clinical practice.
“We are advancing the scientific understanding of skin diseases to develop innovative treatments aimed at addressing real patient needs. Our EADV programme shows the breadth and depth of our work in research and development and is testament to our focus on generating evidence across our broad dermatology portfolio addressing areas of high unmet need,” said Dr Karl Ziegelbauer, Chief Scientific Officer at Almirall. “Through our close collaborations with patients and dermatologists and a pipeline solely dedicated to medical dermatology, we deepen our understanding of the broader burden of skin disease and show where science can make a meaningful difference to patients and the medical community.”
Atopic dermatitis: consistent evidence across body regions including high-impact areas like the face and neck
Almirall’s AD programme expands the clinical and real-world evidence for lebrikizumab, a high affinity, selective interleukin-13 inhibitor, with a focus on generating robust clinical evidence across body regions, high-impact areas and treatment outcomes in different patient populations.
The Phase 3b ADhope trial[xi],[xii],[xiii], the European observational ADtrust study[xiv],[xv],[xvi], and the German real-world evidence study ADlife contribute findings on skin symptoms, itch and other patient-reported outcomes[xvii],[xviii],[xix]. Together, they build understanding of the treatment’s potential efficacy and effectiveness across clinical-trial and routine-practice settings. Analyses from the ADhope and ADtrust studies specifically examine outcomes in patients with face, neck or hand involvement, addressing skin areas where disease can have a substantial impact on daily life1,2.
Findings from the ADjoin clinical long-term extension study assess skin responses with up to three years of treatment[xx]. In addition, late-breaking results from the Phase 3b ADlong extension study show sustained skin and itch responses in patients with up to five years of lebrikizumab exposure3.
Almirall will also host two AD expert meetings exploring visible disease burden, sustained responses and practical approaches to everyday management, with a particular focus on face and neck involvement:
Interactive Industry AD Hub, Thursday 1 October, 9:15 to 10 am CEST: “Looking Into the Face of AD: Tackling Clinical Cases in Moderate-to-Severe Atopic Dermatitis with Face and Neck Involvement including lebrikizumab.” Chaired by Prof. Christian Vestergaard.
AD symposium, Friday 2 October, 1 to 2 pm CEST: “The Many Faces of AD – Spotlight on Visible Burden, Deep Response, and Simplicity in Everyday Care with Lebrikizumab.” Chaired by Dr. Christine Bangert.
Psoriasis: sustained disease control and treatment outcomes beyond skin clearance
New data on tildrakizumab increases the body of scientific evidence demonstrating robust and durable efficacy across the moderate-to-severe psoriasis journey.
New analyses from reSURFACE 1 suggest that earlier intervention may contribute to better outcomes and long-term disease control in psoriasis, reinforcing the value of targeted, sustained IL-23p19 inhibition[xxi].
Beyond skin clearance, final two-year analyses from POSITIVE report benefits in patients with psoriasis affecting high-impact areas or causing high burden symptoms. Findings include improvements in psychological well-being, quality of life, work productivity and treatment satisfaction, supporting a broader view of treatment outcome and its impact on patients’ daily lives4,5,[xxii].[xxiii].
The data presented by Almirall at this year’s EADV conference further demonstrates the treatment outcomes of tildrakizumab across diverse and challenging patient populations. PROCARE-T highlights consistent effectiveness regardless of prior biologic exposure or disease duration6, while PATH-T demonstrates positive treatment outcomes even in patients with high-impact area involvement, and previous biologic failure7.
Almirall’s psoriasis symposium will explore patient perspectives, psychological well-being and treatment considerations in specific populations that represent higher treatment challenges, including older patients and those with obesity:
Psoriasis Symposium, Thursday 1 October, 5:45 to 6:45 pm CEST: “Redefining Treatment Success in Psoriasis: Moving beyond PASI to sustained disease control,” chaired by Professor Ulrich Mrowietz.
Bringing scientific breakthroughs closer to patients and dermatologists
Beyond the scientific programme, Almirall will raise awareness of the burden of AD with face and neck involvement in patients’ daily lives through its Face It campaign and dedicated booth, and a virtual reality medical training for dermatologists. Visitors to Almirall’s congress booth (X304, X306) will also be able to explore its research and development pipeline through interactive displays. Together, these activities reflect the company’s commitment to advancing the scientific understanding of skin diseases and bringing breakthrough innovation to patients and dermatologists.
Further information on Almirall’s scientific presentations and congress activities is available at EADV 2026 Media Page | Almirall
[i] Vestergaard C et al. Lebrikizumab Real-World Effectiveness and Patient Satisfaction in Patients with Moderate-to-Severe Atopic Dermatitis (AD) and Face or Hand Involvement: 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[ii] Vestergaard C et al. Lebrikizumab Provides Clinically Meaningful Response in Face and Hands in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope 1 Study. EADV Congress 2026 (Encore abstract).
[iii] [ADlong Study] Late-Breaking Abstract: Lebrikizumab 5-Year Long-Term Extension Results in Moderate-to-Severe Atopic Dermatitis (ADlong). EADV Congress 2026 (Late-breaker).
[iv] [POSITIVE Study - HRQoL 2-Year] Health-Related Quality of Life, Work Productivity and Treatment Satisfaction with Tildrakizumab for Up to 2 Years in Patients with Moderate-to-Severe Psoriasis in the POSITIVE Study. EADV Congress 2026 (Almirall De novo publication).
[v] [POSITIVE Study - High-Impact] Beyond Skin Clearance: Long Term Improvement of Psychological Well-Being and Health-Related Quality of Life in High-Impact Area Psoriasis Treated with Tildrakizumab (POSITIVE Study). EADV Congress 2026 (Almirall Encore publication).
[vi] [PROCARE-T Study] High effectiveness of tildrakizumab in moderate-to-severe psoriasis regardless of prior biologic therapy or disease duration: 28-week interim data from the PROCARE-T study. EADV Congress 2026 (Almirall publication).
[vii] [PATH-T Study] High effectiveness of tildrakizumab in moderate-to-severe psoriasis involving high-impact areas after failure of prior biologics: 28-week interim data from the PATH-T study. EADV Congress 2026 (Almirall publication).
[viii] Torres T, Fernández-Armenteros JM, Castilla-Fernández G, Asensio D, Galván J. Adherence to Wynzora in adults with mild-to-moderate psoriasis: Results from the ADHER-TOP study. EADV Congress 2026.
[ix] Torres T, Fernández-Armenteros JM, Castilla-Fernández G, Asensio D, Galván J. Effectiveness and PROs of Wynzora in adults with mild-to-moderate psoriasis: Results from the ADHER-TOP study. EADV Congress 2026.
[x] Welzel J, Szepietowski JC, Ferrandiz Pulido C, Pellacani G, Mosterd K, Otero R, Perez Fierro AM, Castilla-Fernández G, Siddall H, Pau-Charles I, Dirschka T. Efficacy, tolerability and 1-year long term safety with tirbanibulin 1% ointment in patients with actinic keratosis applied over a field up to 100 cm² and up to 2 treatment courses. EADV Congress 2026 (Abstract N°: AS-554).
[xi] Irvine A et al. Lebrikizumab Treatment Led to Low Disease Activity in the Majority of Patients with Moderate-to-Severe Atopic Dermatitis: Findings from the ADhope 1 Trial. EADV Congress 2026.
[xii] Zeidler C et al. Lebrikizumab Delivers Improvements Across Patient-Reported Itch, Sleep, Overall Assessment of Disease Severity and Treatment Satisfaction in ADhope 1. EADV Congress 2026.
[xiii] Munera-Campos M et al. Lebrikizumab Shows Efficacy in Patients with Moderate-to-Severe Atopic Dermatitis, Including Patients with Predominantly Moderate Disease (ADhope 1). EADV Congress 2026 (Encore abstract).
[xiv] Augustin M et al. Baseline Demographics, Clinical Characteristics and Disease Burden Among Patients with Atopic Dermatitis (AD) Treated with Lebrikizumab in Real-World Clinical Practice: Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xv] Gutermuth J et al. Lebrikizumab Impact on Alleviating Disease Severity, Itch Burden and Quality of Life, in Patients with Moderate-to-Severe Atopic Dermatitis (AD): 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xvi] Augustin M et al. Lebrikizumab Impact on Patient-Reported Outcomes (PROs) Among Patients with Atopic Dermatitis (AD) in Real-World Clinical Practice: 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xvii] Lauffer F et al. Lebrikizumab Provided High Levels of Effectiveness in Patients with Moderate-to-Severe Atopic Dermatitis: Results from ADlife, A Real-World Study. EADV Congress 2026.
[xviii] Lauffer F et al. Lebrikizumab Treatment Leads to Relevant Improvements in Patient-Reported Outcomes for Moderate-to-Severe Atopic Dermatitis in a Real-Life Setting: Findings from ADlife. EADV Congress 2026.
[xix] Lauffer F et al. Lebrikizumab Provided Meaningful Improvements in Patient-Reported Disease Control and Reduced the Number of Flares in Patients with Moderate-to-Severe Atopic Dermatitis: ADlife Real-World Study. EADV Congress 2026.
[xx] Thaçi D et al. Lebrikizumab Achieved High Levels of Absolute EASI Optimal Response in Patients with Moderate-to-Severe Atopic Dermatitis for Up to 3 Years (ADvocate 1 & 2 to ADjoin). EADV Congress 2026.
[xxi] [reSURFACE 1 Post Hoc] Association Between Psoriasis Duration and Maintenance of Control (PASI ≤2) after Tildrakizumab Withdrawal: Post Hoc Analyses from reSURFACE 1. EADV Congress 2026 (Almirall De novo publication).
[xxii] [POSITIVE Study - Holistic View] A Holistic View of Treatment Success in Psoriasis: Long-Term Real-World Improvements in Psychological Well-Being and Health-Related Quality of Life With Tildrakizumab Patients with Psoriasis and Burdensome Symptoms (POSITIVE study). EADV Congress 2026 (Almirall De novo publication).
[xxiii] [POSITIVE Study - Psycholag] Psycholag in Moderate-to-Severe Psoriasis: Insights from the POSITIVE Study on Psychological Well-being and Treatment with Tildrakizumab. EADV Congress 2026 (Almirall De novo publication).
Press release
PDF 313.7KB
Published on 23 September 2026
Next week, we will be in Vienna for EADV 2026, one of the leading international congresses in dermatology, bringing together healthcare professionals, researchers, industry experts, and partners from around the world to share knowledge and explore the latest advances in skin health.
As a Gold Sponsor, we are proud to be part of this important scientific event and to contribute to the conversations shaping the future of Medical Dermatology. EADV provides a valuable platform for collaboration, learning, and the exchange of perspectives on some of the most pressing challenges and opportunities in dermatology today.
Throughout the congress, our teams will engage with the global dermatology community, participate in scientific discussions, and showcase our ongoing commitment to advancing Medical Dermatology through innovation, research, and partnership. The event also offers an opportunity to connect with peers and experts from across the field, fostering meaningful dialogue that ultimately supports better outcomes for people living with skin diseases.
During the week, we will be sharing highlights from the congress, key scientific insights, and moments from Vienna across our digital channels, offering a glimpse into the discussions and developments influencing the future of dermatological care.
EADV 2026 represents another opportunity to reinforce our commitment to supporting the dermatology community and advancing skin health to improve patients lives.
See you in Vienna!
#WeAreAlmirall #EADV2026
Published on 21 September 2026
As European Mobility Week highlights the importance of cleaner, more sustainable urban transport, we are proud to share how Almirall is advancing its climate ambitions through responsible mobility initiatives.
As part of our Act4Impact 2030 Sustainability Strategy, we are working to reduce the carbon footprint. One of the key ways we are doing this is through the gradual electrification of our fleet. By transitioning both sales and corporate vehicles to electric and hybrid alternatives, we are taking meaningful steps to lower emissions and support our broader climate goals.
However, sustainable mobility goes beyond the vehicles we use. It is also about the choices we make every day. Across our offices, we encourage employees to embrace lower-emission commuting options, including public transportation, walking, and cycling.
These initiatives reflect our belief that meaningful progress is achieved through collective action. Small changes, when adopted consistently across an organization, can contribute to significant long-term impact. By integrating sustainability into the way we move, we are helping build a culture that supports both environmental responsibility and employee wellbeing.
Our commitment to sustainable mobility is part of a broader ambition to create lasting value for people, society, and the planet through science-led action and measurable progress. Because when it comes to addressing climate change, every journey counts.
Discover more about our sustainability commitments and Act4Impact 2030 strategy: https://www.almirall.com/company/sustainability
Published on 17 September 2026
What does patient safety mean when living with a chronic skin condition?
On World Patient Safety Day, we join the World Health Organization in highlighting the importance of keeping patient safety at the center of every medical decision. For people living with conditions such as psoriasis, treatment is an ongoing journey that requires continuous care, monitoring, and support.
At Almirall, pharmacovigilance plays a key role in helping protect patients throughout their long-term journey. By continuously collecting and evaluating safety information from patients, healthcare professionals, clinical studies, and real-world use, we can identify potential safety signals and take timely action to help minimize risks.
To mark this day, colleagues from across Almirall shared what long-term safety means for them. Their perspectives highlight the importance of maintaining a patient-centered approach throughout the entire care journey.
This initiative reflects our commitment to advancing dermatological science while keeping patient well-being and safety at the core of everything we do. Because effective care is about more than managing a condition, it is about helping patients feel supported and protected every step of the way.
Published on 14 September 2026
What if the most challenging part of atopic dermatitis isn't always what we can see?
This World Atopic Eczema Day, we are proud to launch Atopics, an awareness film created with the support of AADA to bring greater understanding to the lived experience of people with atopic dermatitis. While the visible signs of the condition are often recognized, many of its day-to-day challenges remain unseen. Through authentic stories and a human perspective, the film shines a light on these experiences, particularly when the condition affects highly visible areas such as the face.
At Almirall, we believe that advancing understanding in medical dermatology requires more than scientific knowledge alone. It also means listening to patients, amplifying their voices, and fostering empathy alongside scientific rigor. By helping people see beyond the visible symptoms, we hope to contribute to a deeper awareness of the real impact atopic dermatitis can have on daily life.
In support of this commitment, we developed the Atopics campaign to encourage reflection, understanding, and conversation. Through personal stories, the film highlights the experiences behind the condition, reminding us that every patient journey is unique and deserving of recognition.
This initiative reflects our ongoing dedication to raising awareness of dermatological conditions and supporting a more informed and compassionate dialogue around skin health. Because behind every visible symptom, there is a person, a story, and an experience that deserves to be understood.
We invite you to watch Atopics and discover the people behind atopic dermatitis: https://www.almirall.com/patients/commitment/campaigns
Published on 2 September 2026
At Almirall, sustainability is an integral part of how we create long-term value and contribute positively to society. Guided by our Act4Impact strategy, we continuously work to embed responsible business practices into the way we operate, make decisions and drive innovation across our organisation.
This commitment has once again been recognised by EcoVadis. For the sixth consecutive year, we have been awarded the Platinum Medal, maintaining an outstanding score of 92/100 and placing us among the top 1% of more than 175,000 companies assessed worldwide.
More than a recognition, this achievement reflects the dedication of our teams, the strength of our governance and our collective effort to integrate sustainability into our everyday actions. It demonstrates how a shared commitment can help create meaningful impact for patients, society, our partners and the environment.
Being Uncommon By Nature means continuously challenging ourselves to do better and create lasting value. Through collaboration, accountability and a long-term perspective, we remain committed to advancing our sustainability ambitions and contributing to a more sustainable future for generations to come.
This milestone belongs to all the people across Almirall whose daily efforts make our progress possible, and it inspires us to continue turning commitment into action through Act4Impact.
